Moderna, Inc. and Recipharm, a contract development and manufacturing organization (CDMO), have entered an agreement to support formulation and fill-finish a part of the Moderna COVID-19 vaccine supply outside of the U.S. Recipharm will provide these services from its drug product manufacturing facility in France.   Subject to regulatory approval of the vaccine in relevant countries outside of the U.S., it’s anticipated that supply will begin in early 2021.   “We are making important progres...